Novo Integrated Sciences, Inc. (NASDAQ:NVOS – Get Rating) was the target of a significant drop in short interest in the month of April. As of April 30, short interest totaled 141,000 shares, down 52.6% from the April 15 total of 297,600 shares. Based on an average trading volume of 68,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.6% of the company’s stock is sold short.
Shares of NASDAQ:NVOS rose $0.05 on Friday midday to hit $2.05. The company had a trading volume of 12,672 shares compared to an average volume of 35,224. The company has a gearing ratio of 0.24, a current ratio of 1.65 and a quick ratio of 1.62. The company’s 50-day moving average price is $2.26 and its 200-day moving average price is $1.71. Novo Integrated Sciences has a 1 year low of $1.02 and a 1 year high of $3.32.
Novo Integrated Sciences (NASDAQ:NVOS – Get Rating) last announced its earnings results on Wednesday, April 13th. The company reported earnings per share (EPS) of $0.12 for the quarter. The company had revenue of $2.87 million for the quarter. Novo Integrated Sciences had a negative net margin of 80.71% and a negative return on equity of 16.63%.
Major investors recently added to or reduced their stakes in the stock. Morgan Stanley acquired a new stake in Novo Integrated Sciences stock valued at approximately $288,000 during the second quarter. Millennium Management LLC purchased a new position in Novo Integrated Sciences for approximately $111,000 during the second quarter. BlackRock Inc. increased its stake in Novo Integrated Sciences by 114.5% in the first quarter. BlackRock Inc. now owns 23,682 shares of the company’s stock valued at $54,000 after purchasing an additional 12,644 shares during the period. Finally, Citadel Advisors LLC bought a new position in Novo Integrated Sciences for approximately $30,000 during the second quarter. 11.99% of the shares are currently owned by institutional investors and hedge funds.
Company Profile of Novo Integrated Sciences (received rating)
Novo Integrated Sciences, Inc, along with its subsidiaries, provides multidisciplinary primary care products and services. It operates through two segments, healthcare services and product manufacturing and development. The company offers Physical Therapy, Chiropractic, Manual/Manipulative Therapy, Occupational Therapy, Elderly Care, Massage Therapy, Acupuncture and Functional Dry Needling, Podiatry, Stroke and Traumatic Brain Injury/Neurological Rehabilitation, Kinesiology, Vestibular Therapy, Concussion Management and Basic Testing, Trauma Sensitive Yoga and Meditation Concussion Brain Injuries and Work-Related Stress PTSD, Women’s Pelvic Health Program, Sports Medicine Therapy, Assistive Devices, Nutritionist, Holistic Nutrition, Fall Prevention Training, Sports Team Training Program and Private Personal Training Services.
Receive news and reviews for Novo Integrated Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Integrated Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.